Introduction
Lung cancer is currently the leading cause of death from all cancers in the United States (Jemal et al., 2010) . Despite the use of aggressive medical therapy, non-small cell lung cancers (NSCLCs), a major subset of lung cancers, have an overall 5-year survival rate of less than 15% (Jemal et al., 2007) . Recently, the cancer stem cell hypothesis has been applied extensively to solid tumors, such as lung tumors, in addition to hematopoietic cancers (Al-Hajj et al., 2003; Hemmati et al., 2003; Singh et al., 2003; Galli et al., 2004; Bapat et al., 2005; Collins et al., 2005; Fang et al., 2005; Dalerba et al., 2007; O'Brien et al., 2007; Ricci-Vitiani et al., 2007; Eramo et al., 2008; Schatton et al., 2008) . As such, much research has gone into uncovering the different populations of progenitor cells within the lung. These are considered to be a rare population of undifferentiated cells with enhanced ability to proliferate, self-renew, and eventually differentiate into phenotypically diverse and heterogeneous cell populations (Kim et al., 2005) .
The CCAAT/enhancer-binding protein (C/EBP) family of transcription factors is known to affect different aspects of development and differentiation in the lung (Cassel and Nord 2003) . In particular, expression of C/EBPa has been shown to be crucial for lung development, as knockout mice exhibit massive hyperproliferation of type II pneumocytes and do not survive after birth (Flodby et al., 1996) . C/EBPa may act as a tumor suppressor in the lung, as its overexpression in lung tumor cells results in a dramatic decrease in cell proliferation (Halmos et al., 2002) , and it is often downregulated in NSCLC (Halmos et al., 2002; Costa et al., 2007) . Work done by Pear and colleagues showed that the human homolog of the Drosophila tribbles protein, TRIB2, associates with and inhibits the transcriptional activity of C/EBPa (Keeshan et al., 2006; Dedhia et al., 2010) . Additionally, overexpression of TRIB2 induces acute myelogenous leukemia in mice through inactivation of C/ EBPa (Keeshan et al., 2006) , and downregulation of the tumor suppressor gene FOXO3a is mediated by TRIB2 in human melanoma cells (Zanella et al., 2010) .
Based, in part, on these reports, we examined the roles of tumor-initiating cells and TRIB2 in lung tumor oncogenesis. Our results show that TRIB2 is overexpressed and often amplified in lung cancer. Upon short hairpin RNA (shRNA)-mediated knockdown of this putative oncogene, tumor cells lines ceased proliferation and failed to produce tumors in vivo when injected into non-obese diabetic/severe combined immunodeficient mice (NOD/SCID) mice. Finally, we show that TRIB2-mediated downregulation of C/EBPa requires the presence of the E3 ligase TRIM21.
Results
TRIB2 is overexpressed and amplified in a subset of human lung cancers It has been established that growth of cell lines under non-adherent spheroid conditions can increase their tumor-initiating capabilities (for example Ricci-Vitiani et al., 2007; Todaro et al., 2007) . To confirm that this was also true for lung cancer cell lines, NCI-H1650 cells that had been grown as monolayers or as spheroids were injected into NOD/SCID mice and tumor growth was measured over time. Cells grown as spheroids were more efficient at initiating tumorigenesis than the corresponding number of cells grown as monolayers (Supplementary Figure S1A ). From this data and supporting literature, we reasoned that a gene upregulated in cancer cells grown as spheroids might be instrumental in lung tumorigenesis. To identify potential drivers of lung tumorigenesis, microarray expression analysis was performed comparing the transcriptional profile of eight NSCLC cell lines grown either as monolayers or as spheroids. From this transcriptional analysis, TRIB2 was identified as significantly overexpressed in the spheroid population in eight out of eight NSCLC cell lines examined (Po0.05; Supplementary Table S2) . TRIB2 overexpression in the spheroid population ranged from 2 to 76-fold over that of the corresponding monolayer culture. Using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) analysis, TRIB2 expression levels in the NSCLC cell lines propagated either as monolayers or non-adherent spheroids were confirmed. There was a significant increase in TRIB2 expression levels in all cell lines grown as spheroids relative to monolayer conditions ( Figure 1a ).
Based upon these results, we hypothesized that TRIB2 may have a role in human lung tumorigenesis. The expression pattern of TRIB2 in 68 human primary lung tumor samples was subsequently examined using microarray-based mRNA expression analyses. mRNA expression levels were normalized to the corresponding control lung tissue before comparison of TRIB2 levels between tumors. TRIB2 was two-to six-fold overexpressed in 29.4% (20 of 68) of bulk, unsorted primary lung tumor samples (Figure 1b and Supplementary  Table S1 ). The variation in TRIB2 expression levels between primary tumor samples could partially be attributed to the percentage of stem-like cells present within the tumor tissue. Immunohistochemical examination of the tumor samples revealed that for some samples, TRIB2 was overexpressed in a high percentage of cells throughout the tumor, whereas for other samples, high TRIB2 expression was localized to a subset of cells within the tumor tissue, and was relatively low in the surrounding tissues ( Figure 1c and Supplementary Figure S1B ). In the latter instances, overall TRIB2 expression appeared to be relatively low, but in fact, there were localized regions with intense staining. The subset of cells exhibiting high TRIB2 expression levels may represent tumor-initiating cell populations ( Figure 1c and Supplementary Figure S1B) .
The TRIB2 gene resides at 2p24, a chromosomal locus prone to frequent breaks and amplifications (Durkin and Glover, 2007) . We examined TRIB2 gene copy number in primary human samples to determine whether increased gene copy number could provide an additional explanation for increased TRIB2 expression. Using single-nucleotide polymorphism analysis, gene amplification surrounding the TRIB2 locus was observed in 8 of the 68 samples (12%) previously analyzed (Supplementary Figure 1C) . In addition, quantitative PCR analysis of an independent cohort of tumor samples revealed significant and specific gene amplification of 7-to 10-fold at the TRIB2 locus when normalized to non-cancerous counterparts for 3 of 14 (21%) tumor samples analyzed (LT4, LT6 and LT12; Figure 1d ). Further, TRIB2 gene amplification was confirmed by fluorescence in situ hybridization analysis in both lung cancer cell lines and in LT12 (Figure 1e ). Specific amplification of the TRIB2 locus was observed in LC-1/sq-SF lung cancer cells, whereas the elevated level of TRIB2 in H2228 cells was found to be due to polyploidy. The lung tumor samples examined were generally diploid, and TRIB2 gene copy numbers roughly matched the values obtained by quantitative PCR (Figure 1d ). These results indicate that TRIB2 is overexpressed in a subset of lung tumors (around 30%), and that in approximately 10-20% of cases, the overexpression stems from gene amplification.
Depletion of TRIB2 gene expression inhibits proliferation, sphere formation and in vivo tumorigenicity Based upon observations that overexpression of TRIB2 has a role in cellular transformation (Keeshan et al., 2006; Dedhia et al., 2010; Zanella et al., 2010) , the effect of modulating TRIB2 levels using shRNA constructs specific for TRIB2 (sh1-4) or a non-targeting control (shNT) was examined. TRIB2 expression was efficiently depleted using independent shRNA constructs ( Figure 2a and Supplementary Figure S2A ) in multiple cell lines. Two shRNA constructs were chosen for further analysis, as they consistently exhibited the greatest level of TRIB2 knockdown ( Figure 2a ). TRIB2 sh1 is directed against the 3 0 non-coding region of TRIB2, whereas TRIB2 sh2 is directed against the coding sequence of TRIB2. Both constructs consistently decreased mRNA levels by B75% (Supplementary Figure S2A) .
Depletion of TRIB2 in two NSCLC lines, NCI-H226 and NCI-H1650 (H226 and H1650, respectively, hereafter), resulted in significant inhibition of cell proliferation ( Figure 2b ). This was accompanied by a modest increase in apoptosis (Supplementary Figure S2B) . The effect of loss of TRIB2 expression on the ability of cells to grow under low-adherence conditions was also examined. Following knockdown of TRIB2 expression, the ability of cells to quickly re-form spheroids was slightly impaired, and there was marked inhibition of sphere formation during long-term culture (Supplementary Figure S2C ). Importantly, the reduction in cell proliferation appears to be specific for transformed cells, as TRIB2 knockdown in normal lung fibroblast and epithelial cells did not inhibit proliferation (Supplementary Figure S2D -E). Together, these data suggest that TRIB2 specifically affects the proliferative capacity of lung cancer cells, and may have a role in cancer stem cell self-renewal.
To more closely mimic the tumor microenvironment, the tumorigenic capacity of cells in which TRIB2 expression had been depleted was assayed in vivo by injection into NOD/SCID mice. H226 or H1650 cells with confirmed knockdown phenotypes were embedded in collagen or matrigel, and injected subcutaneously. Mice injected with mock-infected cells quickly developed large tumors, as did cells expressing non-targeting shRNA after a lag period. In contrast, mice injected with cells in which TRIB2 had been knocked down remained tumor free for up to 240 days after transplant (Figure 2c ), at which time the experiment was terminated.
To confirm that inhibition of cell proliferation was indeed due to loss of TRIB2 expression, we performed rescue experiments in which shRNA-resistant TRIB2 cDNAs were overexpressed. Constructs were generated for TRIB2 that either lack the 3 0 non-coding region (Trib2s) and thus are not targeted for degradation by sh1, or are mutated such that they are no longer targeted for degradation by sh2 (Trib2m). The in vitro overexpression of Trib2m protein in lung cancer cell lines stably expressing sh2 was sufficient to rescue inhibition of cell proliferation (Figure 3a , Supplementary Figure S3 ). Similar results were obtained upon rescue of sh1-mediated TRIB2 knockdown with Trib2s (data not shown). We then examined whether introduction of Trib2s and Trib2m in vivo could overcome the antitumorigenic effect of TRIB2 knockdown. H226 or H1650 cells stably expressing sh1 or sh2 were infected with Trib2s or Trib2m, respectively, imbedded in collagen or matrigel and injected into NOD/SCID mice. Overexpression of Trib2m or Trib2s in the presence of shRNA directed against TRIB2 resulted in rapid tumorigenesis (Figure 3b and data not shown).
Thus, both in vitro and in vivo inhibition of lung cancer tumor cell proliferation were specifically caused by inhibition of TRIB2 expression.
TRIB2 knockdown correlates with increased expression and activity of C/EBPa Previously published work has suggested the existence of an interaction between C/EBPa and TRIB2 (Keeshan et al., 2006; Dedhia et al., 2010) , and has shown that C/EBPa is expressed in lung cells during development (Flodby et al., 1996) . When TRIB2 expression levels are decreased, several lung cancer cell lines exhibit dramatic phenotypic changes (Figure 4a ). As TRIB2 has been shown to be responsible for both downregulation of C/EBPa and inhibition of cell differentiation (Keeshan et al., 2006; Naiki et al., 2007; Dedhia et al., 2010) , we investigated whether the morphological changes observed upon TRIB2 knockdown in lung cancer cell lines could be due to increased levels of C/EBPa. Indeed, overexpression of C/EBPa in H226 cells resulted in morphological changes similar to those seen upon TRIB2 knockdown (Figure 4a ). To further characterize these changes, immunofluorescence was performed using various lung lineage markers (Kim et al., 2005) . Parental H226 and H226shNT cells retained multiple lineage markers indicative of a more primitive cell type, whereas cells that had been infected with sh1 or sh2 to knockdown TRIB2 expression became restricted to either the alveolar type I or II lineages (Supplementary Figure S4A) . This result is consistent with the reported role of C/EBPa as a necessary factor for differentiation during development (Flodby et al., 1996) , and suggests that upon TRIB2 knockdown, C/EPBa levels increase and drive lung cancer cell differentiation.
As the phenotypic changes observed upon TRIB2 knockdown were similar to the phenotypic changes induced by C/EBPa overexpression in lung cancer cell lines (Figure 4a ), C/EBPa levels were also examined in primary lung tumor samples. Pearson product-moment correlation analysis of microarray data of the same 68 primary samples detailed in Figure 1 indicates a negative correlation between TRIB2 and C/EBPa expression (À0.306, Po0.02; Supplementary Figure S4B ). To confirm this correlation, qRT-PCR was performed on an independent cohort of primary lung tumor cDNAs, and a significant inverse correlation between TRIB2 and C/EBPa expression levels was again observed (Figure 4b ). This indicates that, similar to mouse acute myelogenous leukemia studies (Keeshan et al., 2006; Dedhia et al., 2010) , TRIB2 expression might affect the level of C/EBPa expression in human lung cancer.
To determine whether TRIB2 also affects the transactivation capabilities of C/EBPa, a transient transfection system in which forced expression of C/EBPa leads to luciferase reporter activation was employed. Specifically, a stable 293T cell line that expresses a luciferase reporter behind a 4 Â C/EBPbinding site was generated, and transient transfections of TRIB2, C/EBPa or both species simultaneously were performed. Transfection of the reporter with C/EBPa TRIB2 in lung cancer KB Grandinetti et al alone led to reporter activation approximately 10-fold greater than background levels (Figure 4c ). In contrast, cotransfection of both C/EBPa and TRIB2 reproducibly resulted in a three-fold decrease in reporter activation (Figure 4c) . Although there was a reduction in reporter activity, C/EBPa protein levels were not affected (Figure 4c) . Thus, although coexpression of TRIB2 and C/EBPa leads to a decrease in C/EBPa transactivation activity, it is not due to degradation of C/EBPa.
To further validate the observation that TRIB2 expression affects C/EBPa function, the expression levels of C/EBPa target genes were examined after modulation of TRIB2 levels. After knockdown of expression of TRIB2 using shRNA constructs was confirmed using qRT-PCR and upregulation of C/EBPa was confirmed by western blotting (Figure 4d and Supplementary Figure S4C , respectively), expression of the C/EBPa target genes GCSFR (CSF3; Smith et al., 1996) and NE2 (Oelgeschlager et al., 1996) were examined (Figure 4d ). The expression levels of both C/ EBPa target genes were increased as much as 5-to 10-fold when TRIB2 expression levels were reduced. This finding further supports the hypothesis that expression of TRIB2 inhibits C/EBPa activity. , and all-trans retinoic acid (ATRA, for granulocyte colony-stimulating factor receptor) or granulocyte colonystimulating factor (for neutrophil elastase) was added to the culture media. Cells surviving puromycin selection were collected on day 4. Error bars represent standard deviation.
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TRIB2 interacts with TRIM21 and leads to degradation of C/EBPa
The ability of TRIB2 to affect C/EBPa activity could occur through at least two mechanisms. TRIB2 might bind C/EBPa directly and prevent its transactivation capabilities. Alternatively, the ability of TRIB2 to modulate expression of C/EBPa has been hypothesized to occur via targeting of the transcription factor for proteasomal degradation (Keeshan et al., 2006; Dedhia et al., 2010) , although the exact mechanism remains unknown. To distinguish between these two possibilities and identify protein interactors of TRIB2, immunoprecipitation-mass spectrometry was performed. H1650 cells were retrovirally transduced with a C-terminal FLAG-6xHis dual-affinity-tagged TRIB2 or with a TRIB2 construct devoid of the C-terminal dual-affinity tag as a negative control. Clarified lysates were subjected to dual-affinity purification, and bound proteins were identified by mass spectrometry. The E3 ubiquitin ligase TRIM21 (also called Ro52; (Wada and Kamitani 2006; Wada et al., 2009) ) was clearly identified in the affinity-tagged construct sample but not observed in the negative control experiment (Supplementary Table S3 ). Coprecipitation of TRIB2 and TRIM2 in TRIB2-overexpressing H226 cells confirmed the TRIB2/TRIM21 protein interaction (Figure 5a ). This, in combination with our results and previously published results detailing the regulation of C/EBPa by TRIB2 (Keeshan et al., 2006; Dedhia et al., 2010) , suggests that TRIM21 might be an E3 ubiquitin ligase responsible for targeting C/EBPa for degradation in lung cancer, and that interaction between TRIM21 and TRIB2 is important to this process. To test the hypothesis that TRIM21 has a role in regulation of C/EBPa levels, a 293T transient transfection system was utilized. Cotransfection of C/EBPa and TRIB2 in the absence of TRIM21 resulted in very little or no degradation of C/EBPa (Figure 5b, lane 1) . Likewise, cotransfection of TRIM21 and C/EBPa resulted in little or no change in C/EBPa levels (Figure 5b, lane 3) . However, cotransfection of all three species led to a significant decrease in C/EBPa levels ( Figure 5b, lane 2) . The apparent reduction in TRIM21 expression may be due to TRIM21 autoubiquitination and subsequent degradation (Sabile et al., 2006) . Taken together, these results suggest that both TRIB2 and TRIM21 are necessary for modulation of C/EBPa levels.
Discussion
The transcription factor C/EBPa has been shown to be a major player in lung differentiation, and recent reports have suggested that loss of C/EBPa expression may be instrumental in driving the formation of lung adenomas (Koschmieder et al., 2009) . Although loss of the chromosomal region surrounding C/EBPa is a common feature of up to 50% of NSCLCs, sequencing studies by several groups failed to identify mutations within the coding region of the gene itself, suggesting an alternative mechanism for C/EBPa downregulation (Koschmieder et al., 2009) . One possible mechanism may involve proteasomal degradation of the transcription factor driven by expression of TRIB2 (Grosshans and Wieschaus 2000; Mata et al., 2000; Seher and Leptin 2000; Naiki et al., 2007; Dedhia et al., 2010; Keeshan et al., 2006 Keeshan et al., , 2010 . The results presented here support this hypothesis, and further suggest that TRIM21 may be the E3 ubiquitin ligase necessary for C/EBPa degradation. Additionally, the juxtaposition of the reporter data (Figure 4c ) and the C/EBPa degradation data (Figure 5b ) suggest that although TRIB2 alone is sufficient to block the transcriptional activity of C/EBPa, TRIM21 expression is necessary for downregulation of C/EBPa levels.
Formation of the TRIB2/TRIM21 complex and subsequent downregulation of C/EBPa suggest that TRIB2 may function as a molecular adapter, facilitating assembly of a TRIM21 E3 ligase complex and aiding in the subsequent ubiquitylation and degradation of its substrates, such as C/EBPa. A similar property for the protein kinase dual specificity tyrosine phosphorylation regulated kinase 2 (DYRK2) has been identified, in which DYRK2 functions as a scaffold that mediates assembly of the EDVP E3 ligase complex (Maddika and Chen, 2009 ). Depletion of DYRK2 by small interfering RNA disrupts formation of the EDVP complex. Additionally, the kinase activity of DYRK2 is necessary for substrate ubiquitylation and degradation by the EDVP complex. TRIB2 may perform a scaffolding function similar to DYRK2, although it may not possess the phosphorylation capabilities, as TRIB2 has TRIB2 in lung cancer KB Grandinetti et al been proposed to be a pseudokinase (Hegedus et al., 2007) .
An interaction between TRIB2 and the E3 ligase COP1 has previously been reported Keeshan et al., 2010) . The apparent ability of TRIB2 to bind to multiple E3 ligase proteins also supports the hypothesis that TRIB2 functions as a molecular scaffold, and is involved in many processes including C/EBPa degradation via the proteasome. Using an unbiased immunoprecipitation-mass spectrometry approach, we did not observe interaction between TRIB2 and COP1 in lung cancer cell lines, even though COP1 was expressed in those cell lines (data not shown). Perhaps the interaction of TRIB2 with different E3 ligases is context dependent, with the TRIB2/COP1 interaction involved in hematopoietic tumor generation, whereas TRIB2/TRIM21 is involved in solid tumor formation such as lung tumors.
Based on our results and those of others (Keeshan et al., 2006; Dedhia et al., 2010) , we propose the following hypothesis for TRIB2 protein interactions and subsequent activities: C/EBPa functions as a transcription factor in the absence of TRIB2 (Figure 5ci ). When TRIB2 is present and bound to C/EBPa, transcriptional activity is lost, possibly because of its inability to bind DNA (Figure 5cii ). Upon recruitment of TRIM21 to the TRIB2:C/EBPa complex, C/EBPa is degraded in a proteasome-dependent manner (Figure 5ciii) . Thus, when TRIM21 is present, increased TRIB2 expression will result in a decrease in CEBPa levels. Moreover, as C/ EBPa has been shown to undergo autoregulation (Timchenko et al., 1995) , decreased levels of the protein will lead to continued downregulation at the mRNA level.
As TRIM21 appears to mediate the effects of TRIB2, modulation of TRIM21 should phenocopy TRIB2 modulation. However, it has recently been shown that loss of TRIM21 results in the induction of a massive cytokine response, leading to cell death (Yoshimi et al., 2009) . Thus, we were unable to confirm the expected phenocopy (data not shown).
Here, we described the role of TRIB2 as a potential oncogene in human lung cancers. We found that the gene is enriched in cells grown as spheroids and, importantly, is overexpressed in a significant percentage of primary lung tumors. Further, we found that this overexpression could be due to genomic amplification of the gene. This finding could enable both better diagnostics and screening for lung cancer as well as improved predictions of lung cancer outcomes. Additionally, inhibition of overexpressed and/ or amplified TRIB2 in lung cancers could provide a possible means of treatment, as our results indicate that reducing levels of TRIB2 can efficiently inhibit tumor growth. Together, our findings indicate that overexpression of TRIB2 inhibits the expression of C/EBPa through multiple mechanisms, including transcriptional inactivation and protein degradation, and could consequently lock cells in an undifferentiated, tumor-initiating cell state.
Materials and methods
Primary lung tumor samples, cell proliferation and tumorigenicity The human primary tumor samples utilized in this study consisted of matched pairs including a bulk tumor sample and adjacent non-tumorous lung tissue from the same patient. They were obtained from Asterand (Detroit, MI, USA; Supplementary Table S1 ), with approval from the appropriate institutional review boards. Total RNA, complementary DNA (cDNA) or genomic DNA were either obtained directly from Asterand (Figure 1b, Supplementary Figure S1C and S4B) and Origene (Rockville, MD, USA; Figure 4b ) or were extracted from bulk tissue samples and used to generate DNA (Qiagen, Valencia, CA, USA; Figure 1d ). To assess cell proliferation, cells were seeded at 5000 cells/well in 96-well tissue culture plates and analyzed using CellTiterGlo (Promega, Madison, WI, USA). Tumor growth studies in NOD/SCID mice were performed according to the National Institutes of Health guidelines with protocols approved by the institutional review board of the Genomics Institute of the Novartis Research Foundation.
Constructs and lentiviruses
A 1032-bp fragment encoding the entire human TRIB2 cDNA was subcloned into pcDNA3.1/V5/HIS (Invitrogen, Carlsbad, CA, USA) and pHAGE/CMV/MCS/IRES/ZSgreen vectors (Pan et al., 2008) . To generate the Trib2m mutant, silent mutations of the TRIB2 sh2-binding region were introduced by site-directed mutagenesis. Lentiviral vectors expressing shRNA sequences directed against human TRIB2 (sh1-sh4) as well as a non-targeting construct (shNT) were obtained from Sigma-Aldrich (St Louis, MO, USA). The C/EBPa luciferase reporter vector has previously been described (Behre et al., 2002) .
Other experimental methods Additional details and methodologies regarding cell culture, antibodies, microarray procedures, constructs, lentiviruses, immunohistochemistry, immunofluorescence, expression analysis, immunoprecipitations, in vivo tumorigenicity, gene copy number analysis and mass spectrometry can be found in the Supplementary Methods.
